BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1113 related articles for article (PubMed ID: 750606)

  • 1. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of vitamin D: current status.
    DeLuca HF
    Am J Clin Nutr; 1976 Nov; 29(11):1258-70. PubMed ID: 187053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK; Lyles KW; Haussler MR; Harrelson JM
    J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of vitamin D on bone in vivo.
    Tam CS; Heersche JN; Jones G; Murray TM; Rasmussen H
    Endocrinology; 1986 Jun; 118(6):2217-24. PubMed ID: 3486118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in our understanding of the vitamin D endocrine system.
    De Luca HF
    J Lab Clin Med; 1976 Jan; 87(1):7-26. PubMed ID: 173767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ionic control of 1,25-dihydroxyvitamin D3 production in isolated chick renal tubules.
    Bikle DD; Rasmussen H
    J Clin Invest; 1975 Feb; 55(2):292-8. PubMed ID: 236326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
    Norman AW; Sergeev IN; Bishop JE; Okamura WH
    Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kidney as an endocrine organ involved in the function of vitamin D.
    DeLuca HF
    Am J Med; 1975 Jan; 58(1):39-47. PubMed ID: 163578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse.
    Marie PJ; Travers R; Glorieux FH
    Calcif Tissue Int; 1982 Mar; 34(2):158-64. PubMed ID: 6282410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3.
    Hughes MR; Baylink DJ; Jones PG; Haussler MR
    J Clin Invest; 1976 Jul; 58(1):61-70. PubMed ID: 1084355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gautvik KM; Gordeladze JO
    Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone and serum concentrations of osteocalcin as a function of 1,25-dihydroxyvitamin D3 circulating levels in bone disorders in rats.
    Lian JB; Carnes DL; Glimcher MJ
    Endocrinology; 1987 May; 120(5):2123-30. PubMed ID: 3494594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] metabolism in vitamin D-deficient rats infused with 1,25-(OH)2D3.
    Yamato H; Matsumoto T; Fukumoto S; Ikeda K; Ishizuka S; Ogata E
    Endocrinology; 1989 Jan; 124(1):511-7. PubMed ID: 2783309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL; Felsenfeld AJ; Llach F
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone].
    Ritz E; Kreusser W; Boland R; Bommer J
    Klin Wochenschr; 1979 Oct; 57(19):1053-9. PubMed ID: 392179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects.
    Nielsen HK; Thomsen K; Eriksen EF; Charles P; Storm T; Mosekilde L
    Bone Miner; 1988 Apr; 4(1):105-13. PubMed ID: 3263890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.